Oramed Pharmaceuticals (ORMP) Return on Sales (2016 - 2025)

Oramed Pharmaceuticals has reported Return on Sales for 8 years, with the latest figure at 0.32% in Q4 2025.

• For the quarter ending Q4 2025, Return on Sales changed N/A year-over-year to 0.32%; the trailing twelve-month figure through Dec 2025 stood at 0.32% (changed N/A YoY), and the FY2025 full-year result was 0.32%, changed N/A from the prior year.
• Return on Sales for Q4 2025 stood at 0.32%, up from 0.22% in the prior quarter.
• The five-year high for Return on Sales was 0.32% in Q4 2025, with the low at 0.17% in Q2 2022.
• Historically, Return on Sales has averaged 0.04% across 4 years, with a median of 0.09% in 2021.
• The largest YoY upside for Return on Sales was 16 bps in 2023 against a maximum downside of 1 bps in 2023.
• Oramed Pharmaceuticals' Return on Sales stood at 0.09% in 2021, then tumbled by 59 bps to 0.14% in 2022, then soared by 119 bps to 0.03% in 2023, then soared by 1129 bps to 0.32% in 2025.
• The last three Return on Sales figures came in at 0.32% (Q4 2025), 0.22% (Q3 2025), and 0.12% (Q2 2025), per Business Quant data.